Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Synovial Sarcoma, X Breakpoint 2 (SSX2) Peptid

SSX2 Reaktivität: Human Wirt: Synthetic BP, WB
Produktnummer ABIN984471

Kurzübersicht für Synovial Sarcoma, X Breakpoint 2 (SSX2) Peptid (ABIN984471)

Target

SSX2 (Synovial Sarcoma, X Breakpoint 2 (SSX2))

Spezies

Human

Quelle

  • 2
Synthetic

Applikation

Blocking Peptide (BP), Western Blotting (WB)
  • Produktmerkmale

    This is a synthetic peptide designed for use in combination with anti-SSX2 antibody (Catalog #: ARP37719_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.

    Aufreinigung

    Purified
  • Applikationshinweise

    Each Investigator should determine their own optimal working dilution for specific applications.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Lyophilized

    Rekonstitution

    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.

    Konzentration

    1 mg/mL

    Buffer

    Final peptide concentration is 1 mg/mL in PBS.

    Handhabung

    Avoid repeated freeze-thaw cycles.

    Lagerung

    -20 °C

    Informationen zur Lagerung

    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • Target

    SSX2 (Synovial Sarcoma, X Breakpoint 2 (SSX2))

    Hintergrund

    SSX2 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X,18) translocation characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are probably responsible for transforming activity. Two transcript variants encoding distinct isoforms have been identified for this gene.The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X,18) translocation characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are probably responsible for transforming activity. Two transcript variants encoding distinct isoforms have been identified for this gene.

    Alias Symbols: HD21, HOM-MEL-40, MGC119055, MGC15364, MGC3884, SSX, SSX2B, CT5.2a

    Protein Interaction Partner: RAB3IP,SSX2IP,RNF2

    Protein Size: 223

    Molekulargewicht

    25 kDa

    Gen-ID

    6757

    NCBI Accession

    NM_003147, NP_003138
Sie sind hier:
Chat with us!